in which the appellant lives or has his principal place of business, or for the District of Columbia. Appropriate service is provided and a transcript of the proceedings before the Secretary and his findings shall be filed in the court. The court may affirm or set aside the order in whole or in part. The findings of the Secretary as to questions of fact shall be sustained if based upon a fair evaluation of the entire record at the Secretary's hearing. The court shall advance on the docket and expedite the disposition of all cases filed under this section.

The bill provides for the taking of further testimony in certain cases and further procedures in such instances. The judgment of the circuit court is final, subject to review by the Supreme Court.

Paragraph (g) makes any person who knowingly obstructs or interferes with, or conspires with any other person to do so, the performance by any officer or agent of the Department of any duty under this section subject to fine of $500 or imprisonment for not more than one year, or both.

Review Of Official Names of Drugs

Section 509. Section 509 would set up a system for the designation of official names or drugs. Paragraph (a) authorizes the Secretary to determine official names of drugs in the interest of usefulness and simplicity. Only those names approved by the Secretary are to be the official names used in the official compendia. This does not apply to combination of drugs. Here the official names of the component ingredients must be indicated. A manufactrurer, however, is not prohibited from using brand or trade names.

Section 509 of the act as amended by this bill requires the Secretary in paragraph (b) to cause a review to be made of official names or titles by which drugs are identified in the official compendium at least once in an unstated period of years to determine whether revi

sion of any of the names is neces sary or desirable in the interest of usefulness and simplicity. The number of years is to be determ ined after hearings on the bill.

Paragraph (c) of the bill requires the Secretary to designate another official name which will be useful when he finds the official name in use is unduly complex or is not useful. When the Secretary deter mines that there are two or more drugs which are identical in chemical structure and pharmacological action and substantially identical in strength, quality, and purity, he shall designate for such drug or drugs a single official name which is useful. He shall also designate an official name to any drug found not to have such a name.

Under paragraph (d) of the bill after each review of the official compendia and at such other times as the Secretary determines to be desirable, he shall cause to be published a list of all revised official names and such other matters as he deems necessary for the effective use of those drug names.

Paragraph (e) requires the official name caused to be compiled and published by the Secretary shall be the exclusive official name of the drug.

Material for

Physicians' Information

Section 510. A new section 510 will be added to the FD&C Act providing in paragrph (a) that the Secretary publish and distribute to physicians annually, and at such other times as he deems desir able, a list of drugs which have the potentiality of particularly serious, dangerous or harmful ef fects as he may consider in the interest of public health; and in paragraph (b) that the Secretary also publish in convenient and readable form and distribute to doctors, hospitals, medical and nurses training schools, and federal, state and local government offices concerned with handling and utilization of drugs, copies of all printed matter which must be included in any package in which a drug is sold.

Precautions and Contraindications

Although there have been no reports of significant toxic reactions

to Preludin, on theoretical grounds it should not be given to pa tients with severe hypertension, thyrotoxicosis or acute coronary disease.

Preludin may be used with caution in cases of moderate hypertension and cardiac decompensation

Preludin, brand of phenmetrazine hydrochloride.
Under license from C H Boehringer Sohn, Ingelheim.

7-61

48